QURE: uniQure N.V. | TickerTools

Price Chart

Key Statistics

Market Cap(EOD)728.63M

Enterprise Value541.55M

P/E Ratio (TTM)-3.66

P/B Ratio (TTM)-181.83

P/S Ratio (TTM)50.82

Earnings Yield (TTM)-27.34%

ROE (TTM)-1010.74%

ROIC (TTM)-30.88%

Net Profit Margin (TTM)N/A

Dividend Yield (TTM)N/A

Payout Ratio (TTM)N/A

Debt/Equity (TTM)-16.66

About uniQure N.V.

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.